In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on Spectrum Pharmaceuticals (SPPI – Research Report), with a price target of $4.00. The company’s shares opened today at $0.40.
According to TipRanks, White is an analyst with an average return of -21.8% and a 26.45% success rate. White covers the Healthcare sector, focusing on stocks such as TRACON Pharmaceuticals, Spectrum Pharmaceuticals, and G1 Therapeutics.
In addition to H.C. Wainwright, Spectrum Pharmaceuticals also received a Buy from JMP Securities’s Reni Benjamin in a report issued on November 21. However, on November 16, B.Riley Financial downgraded Spectrum Pharmaceuticals (NASDAQ: SPPI) to a Hold.
SPPI market cap is currently $87.32M and has a P/E ratio of -0.68.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development, and commercialization of pipeline of late-stage clinical and commercial products. It operates through the following brands: FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ, and EVOMELA. The company was founded in December 1987 and is headquartered in Henderson, NV.
Read More on SPPI: